Mandate

VINGE ADVISES ON OPUS GROUP’S RIGHTS ISSUE

Vinge is advising Opus Group in connection with a rights issue of approximately SEK 150 million. The rights issue is conditional upon approval by the members at an extraordinary general meeting to be held on 10 March 2015. The board of directors will determine the terms and conditions governing the rights issue not later five days prior to the record day. A prospectus is expected to be published on 11 March 2015 and the subscription period is 17-31 March 2015.

Vinge’s team advising on the preparation of the prospectus and capital markets issues consists of responsible partner Anders Strid together with associates Daniel Lennartsson, Frida Bäckgren and Anna Hofling Johansson (tax).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026